A Single-center retrospective case series clinical study of targeted SARS-CoV-2 treatment in immunocompromised patients with COVID-19
Latest Information Update: 02 Aug 2022
At a glance
- Drugs Casirivimab/imdevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Remdesivir (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
Most Recent Events
- 02 Aug 2022 New trial record